Health Canada has granted conditional approval for the use of Lynparza in combination with abiraterone and prednisone or prednisolone to treat patients with BRCA mutated metastatic castration-resistant prostate cancer. This exciting development is based on the promising results from the Phase 3 PROpel trial, which demonstrated that patients receiving Lynparza/abiraterone experienced improved radiographic progression free survival (rPFS) compared to those receiving placebo/abiraterone. By offering a new treatment option, this approval provides much-needed hope to patients with a poor prognosis and may help reduce the risk of disease progression or death.
Prostate cancer is the most prevalent cancer among Canadian men and ranks as the third leading cause of cancer-related deaths. Within five years of initial therapy, approximately 10-20% of prostate cancer patients develop metastatic castration-resistant prostate cancer. The high mortality rates associated with this form of cancer can be incredibly daunting for patients and their families.